News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
421,139 Results
Type
Article (30848)
Company Profile (112)
Press Release (390179)
Section
Business (109633)
Career Advice (577)
Deals (19027)
Drug Delivery (89)
Drug Development (44958)
Employer Resources (84)
FDA (11190)
Job Trends (10522)
News (190386)
Policy (21812)
Tag
Academia (2276)
Alliances (30953)
Alzheimer's disease (941)
Approvals (11226)
Artificial intelligence (167)
Bankruptcy (150)
Best Places to Work (9339)
Breast cancer (144)
Cancer (1058)
Cardiovascular disease (93)
Career advice (528)
Cell therapy (191)
Clinical research (35393)
Collaboration (460)
COVID-19 (2295)
C-suite (102)
Data (1063)
Diabetes (152)
Diagnostics (4950)
Drug pricing (94)
Earnings (35968)
Employer resources (74)
Events (74755)
Executive appointments (421)
FDA (11864)
Funding (449)
Gene therapy (136)
GLP-1 (422)
Government (4218)
Healthcare (15330)
Infectious disease (2397)
Inflammatory bowel disease (91)
IPO (8065)
Job creations (1628)
Job search strategy (476)
Layoffs (193)
Legal (4205)
Lung cancer (163)
Manufacturing (142)
Medical device (9462)
Medtech (9465)
Mergers & acquisitions (11225)
Metabolic disorders (392)
Neuroscience (1204)
NextGen: Class of 2025 (5157)
Non-profit (4001)
Northern California (1277)
Obesity (220)
Opinion (130)
Patents (89)
People (34680)
Phase I (11377)
Phase II (14410)
Phase III (12195)
Pipeline (454)
Policy (84)
Postmarket research (1736)
Preclinical (5026)
Radiopharmaceuticals (158)
Rare diseases (231)
Real estate (3067)
Regulatory (14671)
Research institute (1994)
Series A (73)
Southern California (995)
Startups (2261)
United States (12113)
Vaccines (548)
Weight loss (136)
Date
Last 7 days (413)
Last 30 days (1674)
Last 365 days (22658)
2025 (3155)
2024 (23063)
2023 (25848)
2022 (35602)
2021 (39169)
2020 (39444)
2019 (34634)
2018 (25988)
2017 (19216)
2016 (20229)
2015 (22853)
2014 (17125)
2013 (13727)
2012 (14552)
2011 (15093)
2010 (13029)
Location
Africa (557)
Arizona (111)
Asia (23418)
Australia (4333)
California (2770)
Canada (1188)
China (252)
Colorado (147)
Connecticut (174)
Europe (51850)
Florida (460)
Georgia (139)
Illinois (324)
Indiana (234)
Japan (96)
Kansas (75)
Maryland (540)
Massachusetts (2245)
Michigan (132)
Minnesota (196)
New Jersey (1022)
New York (934)
North Carolina (587)
Northern California (1277)
Ohio (115)
Pennsylvania (749)
South America (710)
Southern California (995)
Texas (400)
Utah (122)
Washington State (347)
421,139 Results for "merck animal health".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, announced the U.S. Department of Agriculture approval of NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza.
June 25, 2024
·
6 min read
Deals
Merck Animal Health to Acquire Elanco’s Aqua Business
Merck Animal Health announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species.
February 5, 2024
·
7 min read
Earnings
Merck’s Gardasil Woes Grow as China Trade War Heats Up
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
February 4, 2025
·
4 min read
·
Annalee Armstrong
Cancer
Arcus Challenges Merck in Kidney Cancer with Early Data
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, according to analysts at Truist Securities.
February 18, 2025
·
2 min read
·
Tristan Manalac
Pharm Country
Merck Animal Health’s Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association.
January 15, 2024
·
12 min read
Press Releases
Merck Canada urges Canadians to take action for their lung health with new “Listen Close” campaign
February 4, 2025
·
5 min read
Legal
RFK Jr.-Linked Lawsuit Against Merck Suspended After Confirmation:
Reuters
Recently appointed HHS Secretary Robert F. Kennedy Jr. in 2018 helped bring several cases against vaccine maker Merck, alleging injury linked to its HPV shot Gardasil.
February 19, 2025
·
2 min read
·
Tristan Manalac
FDA
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US
Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s greenlight for an injectable formulation of BMS’s cancer blockbuster.
January 2, 2025
·
2 min read
·
Kate Goodwin
Mergers & acquisitions
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from
Reuters
, Merck KGaA confirmed that it is in talks with SpringWorks for a potential acquisition, though details of its offer have yet to be revealed.
February 11, 2025
·
2 min read
·
Tristan Manalac
Cancer
Merck and Epitopea Join Forces to Identify Unknown Tumor Antigens
The agreement, in which Merck will pay the biotech an undisclosed initial sum to license drugs targeting a solid tumor, could net Epitopea up to $300 million down the line.
February 19, 2025
·
1 min read
·
Dan Samorodnitsky
1 of 42,114
Next